Inflammation Research

, Volume 44, Issue 5, pp 217–221 | Cite as

Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor α in the knee-joints of patients with rheumatoid arthritis

  • J. Neidel
  • M. Schulze
  • J. Lindschau
Review
Received:
Revised:
Accepted:

Abstract

Objective

To determine whether concentrations of cytokines and matrix-degrading enzymes in synovial fluid of patients with rheumatoid arthritis or osteoarthritis are associated with the degree of bone-destruction in the same joint.

Methods

Determination of Interleukin-1α, IL-1β, IL-1-receptor-antagonist, IL-6, IL-8, tumor necrosis factorα (by ELISA), collagenase-activity and caseinase-activity (by substrate-assays) in the SF (knee) of patients with RA (n42) or OA (n35). The degree of bone-destruction was assessed radiographically.

Results

SF cytokine- and enzyme-levels were higher in patients with RA than in those with OA. In the RA group, SF-levels of TNFα were positively correlated with the degree of bone destruction of the respective joint. No correlation was found between radiographically assessed joint changes and SF-concentrations of other cytokines, enzyme activities, serum CRP, or duration of disease. In the OA-group, none of the examined parameters was associated with the degree of joint destruction.

Conclusions

Our data may support the assumption of TNFα playing an important role in joint destruction in RA. Possible alternative conclusions are discussed.

Key words

Tumour necrosis factor Rheumatoid arthritis Bone erosions 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Malfait AM, Verbruggen G, Veys EM, Lambert J, de Ridder L, Cornelissen M. Comparative and combined effects of interleukin-6, interleukin-1b, and tumor necrosis factor a on proteoglycan metabolism of human articular chondrocytes cultured in agarose. J Rheumatol 1994;21:314–20.PubMedGoogle Scholar
  2. [2]
    Neidel J, Zeidler U. Independent effects of interleukin 1 on proteoglycan synthesis and proteglycan breakdown of bovine articular cartilage in vitro. Agents Actions 1993;39:82–90.PubMedGoogle Scholar
  3. [3]
    Treadwell BV, Neidel J, Pavia M, Towle CA, Trice ME, Mankin HJ. Purification and Characterization of Collagenase Activator Protein Synthesized by Articular Cartilage. Arch Biochem Biophys 1986;251:715–23.PubMedGoogle Scholar
  4. [4]
    Shingu M, Nagai Y, Isayama T, Naono T, Nobunaga M, Nagai Y. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol 1993;94:145–9.PubMedGoogle Scholar
  5. [5]
    Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163–8.PubMedGoogle Scholar
  6. [6]
    Dayer JM, Derochemonteix B, Burrus B, et al. Human recombinant interleukin-1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest 1986;77:645–8.PubMedGoogle Scholar
  7. [7]
    Heath JK, Saklatvala J, Meikle MC, Atkinson SJ, Reynolds JJ. Pig interleukin 1 is a potent stimulator of bone resorption in vitro. Calcif Tissue Int 1986;37:95–7.Google Scholar
  8. [8]
    Thomas BM, Mundy GR, Chambers TJ. Tumor necrosis factor alpha and beta induce osteoblastic cells to stimulate osteoclast bone resorption. J Immunol 1987;138:775–80.PubMedGoogle Scholar
  9. [9]
    Pettipher ER, Higgs GA, Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci USA 1986;83:8749–53.PubMedGoogle Scholar
  10. [10]
    Tessier P, Audette M, Cattaruzzi P, McColl SR. Up-regulation by tumor necrosis factorα of intercellular adhesion molecule 1 expression and function in synovial fibroblasts and its inhibition by glucocorticoids. Arthritis Rheum 1993;11:1528–39.Google Scholar
  11. [11]
    Fontana A, Hengartner G, Weber E, Fehr K, Grob PJ, Cohen G. Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int 1982;2:49–53.PubMedGoogle Scholar
  12. [12]
    Hopkins SJ, Meager A. Cytokines in synovial fluid: II. The presence of tumor necrosis factor and interferon. Clin Exp Immunol 1988;73:88–92.PubMedGoogle Scholar
  13. [13]
    Kannami K, Mitsuhashi T, Takeshita H, Okada K. Concentration of Interleukin 1 beta in serum and synovial fluid in patients with rheumatoid arthritis and those with osteoarthritis. J Jpn Orthop Assoc 1989;63:1343–52.Google Scholar
  14. [14]
    di Giovine FS, Poole S, Situnayake RD, Wadhwa M, Duff GW. Absence of correlations between indices of systemic inflammation and synovial fluid interleukin 1 (alpha and beta) in rheumatic diseases. Rheumatol Int 1990;9:259–64.PubMedGoogle Scholar
  15. [15]
    Miller VE, Rogers K, Muirden KD. Detection of tumor necrosis factor alpha and interleukin-1 beta in the rheumatoid osteoarthritic cartilage-pannus junction by immunohisto-chemical methods. Rheumatol Int 1993;13:77–82.PubMedGoogle Scholar
  16. [16]
    Roux-Lombard P, Punzi L, Hasler F, et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993;36:485–9.PubMedGoogle Scholar
  17. [17]
    Henderson B, Pettipher ER. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol 1989;75:306–10.PubMedGoogle Scholar
  18. [18]
    Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991;88:1445–51.PubMedGoogle Scholar
  19. [19]
    Malyak M, Swaney RE, Arend WP. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Arthritis Rheum 1993;36:781–9.PubMedGoogle Scholar
  20. [20]
    Roux-Lombard P, Steiner G. Preliminary report on cytokine determination in human synovial fluids: a consensus study of the European Workshop for Rheumatology Research. Clin Exp Rheumatol 1992;10:515–20.PubMedGoogle Scholar
  21. [21]
    Neidel J, Schulze M, Sova L. Insulin-like growth factor I accelerates recovery of articular cartilage proteoglycan synthesis in culture after inhibition by interleukin 1. Arch Orthop Trauma Surg 1994;114:43–8.PubMedGoogle Scholar
  22. [22]
    Swaak AJ, van Rooyen A, Nieuwenhuis E, Aarden LA. Interleukin 6 in synovial fluid and serum of patients with rheumatic diseases. Scand J Rheumatol 1988;17:469–74.PubMedGoogle Scholar
  23. [23]
    Remick DG, deForge LE, Sullivan JF, Showell HJ. Profile of cytokines in synovial fluid specimens from patients with arthritis. Immunol Invest 1992;21:321–7.PubMedGoogle Scholar
  24. [24]
    Gauldi J, Richards G, Harmish D, Lansdrop P, Baumann H. Interferon-β/BSF-2 shares identity with monocyte-derived hepatocyte stimulatory factor (HSF) and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987;84:7251–55.PubMedGoogle Scholar
  25. [25]
    Kishimoto T. The biology of interleukin-6. Blood 1989;74:1–10.PubMedGoogle Scholar
  26. [26]
    Detmers PA, Lo SK, Olsen-Egbert EO, et al. Neutrophil activating protein 1/interleukin 8 stimulates the binding activity of the leukocyte adhesion receptor CD11b/CD18 on human neutrophils. J Exp Med 1990;171:1155–9.PubMedGoogle Scholar
  27. [27]
    Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.PubMedGoogle Scholar
  28. [28]
    Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039–49.PubMedGoogle Scholar
  29. [29]
    Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol 1977;18:481–91.Google Scholar
  30. [30]
    Dahlberg L, Ryd L, Heinegard D, Lohmander LS. Proteoglycan fragments in joint fluid: Influence of arthrosis and inflammation. Acta Orthop Scand 1992;63:417–23.PubMedGoogle Scholar
  31. [31]
    Harris ED. Treatment of rheumatoid arthritis. In: WN Kelley editor. Textbook of Rheumatology, 4th edition. Philadelphia Saunders, 1993.Google Scholar
  32. [32]
    Brennan FM, Maini RN, Feldman M. TNFα — A pivotal role in rheumatoid arthritis? Br J Rheumatol 1992;31:293–8.PubMedGoogle Scholar
  33. [33]
    Fong KY, Boey ML, Koh WH, Feng PH. Cytokine concentrations in the synovial fluid and plasma of rheumatoid arthritis patients: Correlation with bony erosions. Clin Exp Rheumatol 1994;12:55–58.PubMedGoogle Scholar
  34. [34]
    Kahle P, Saal JG, Schaudt K, Zacher J, Fritz P, Pawelec G. Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue. Ann Rheum Dis 1992;51:731–4.PubMedGoogle Scholar
  35. [35]
    Farahat MN, Yanni G, Poston R, Panayi GS. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1993;52:870–5.PubMedGoogle Scholar
  36. [36]
    Taylor DJ. Cytokine combinations increase p75 tumor necrosis factor receptor binding and stimulate receptor shedding in rheumatoid synovial fibroblasts. Arthritis Rheum 1994;37:232–5.PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1995

Authors and Affiliations

  • J. Neidel
    • 1
  • M. Schulze
    • 1
  • J. Lindschau
    • 1
  1. 1.Department of OrthopaedicsThe Center for RheumatologyBad BramstedtGermany

Personalised recommendations